Search results
Added:
1 year ago
In this short interview, Dr Cecilia Linde (Karolinska University, SE) shares the findings of the CCM HFpEF Study.
Originally presented at Heart Failure 22, this study aimed to evaluate the safety and efficacy of
cardiac contractility modulation therapy in heart failure patients with preserved ejection fraction (HFpEF).
Discussion Points:
1. Study Background
2. Study Design & Patient Population
3…
View more
Added:
1 year ago
TCT 22 - In this short interview, Dr Samir Kapadia (Cleveland Clinic, OH, US) outlines the findings of the PROTECTED-TAVR trial, which aimed to demonstrate the performance of Boston Scientific's Sentinel® Cerebral Protection System in transcatheter aortic valve replacement.
In this study, 3000 patients were randomized to receive either TAVR with the Sentinel system or TAVR without intervention…
View more
Added:
3 years ago
High-quality healthcare is that which increases “the likelihood of desired health outcomes and is consistent with standards of health care.”1 Inherent in such a definition is the critical role of measurement of patient outcomes and the ‘standards of healthcare,’ such as those reflected in evidence-based clinical practice guidelines.2 Unfortunately, when the quality of healthcare in the US is…
View more
Added:
3 years ago
A 2011 report from the American Heart Association states that “On the basis of 2007 mortality rate data, more than 2,200 Americans die of CVD every day, an average of 1 death every 39 seconds.”1 The economic cost of cardiovascular disease (CVD) in the US was nearly $286 billion in 2007, which is 15 % of total healthcare expenditure.
There are 13 million people living with a diagnosis of CVD.2…
View more
Added:
3 years ago
Cardiovascular disease (CVD), including myocardial infarction and stroke, is the leading cause of morbidity and mortality in the US. A broad array of randomized trials have demonstrated the benefits of low doses of aspirin (75-325mg)1,2 for both the primary3-7 and secondary8-11 prevention of CVD. Most trials demonstrate a 15-40% reduction in cardiovascular events with chronic aspirin use.Aspirin…
View more
Added:
3 years ago
Approximately five million people present to the emergency department (ED) each year with chest pain, and billions of dollars are spent on assessment and treatment. Many therapies are time-dependent, so rapid identification of patients with acute coronary syndrome (ACS) - unstable angina (UA) and acute myocardial infarction (MI) - at high risk for adverse outcomes is essential. Missed or…
View more
Added:
3 days ago
EHRA 24 - We are joined onsite by Dr Julius Nikorowitsch (University Heart and Vascular Centre Hamburg (UHZ), DE) to outline the impact of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation in a substudy of the NOAH-AFNET 6 trial (NCT02618577).The substudy consisted of 2534 patients from…
View more
Added:
3 years ago
Risk stratification of patients with an acute coronary syndrome (ACS) starts on presentation and is a continuous process to predict those who are at high risk for further ischemic events or adverse outcomes. Among patients with non-ST-elevation myocardial infarction (NSTEMI), risk stratification begins with initial assessment to detect patients at immediate high risk. Subsequent evaluation is…
View more
TAVR Optimization
Added:
2 years ago
Article
Added:
11 months ago
ESC-HFA 23 - Dr Jawad Haider Butt (Copenhagen University Hospital, DK) outlines the findings of a patient-level meta-analysis of the DAPA-HF and DELIVER trials, which studied the safety and effectiveness of dapagliflozin on patients with both peripheral arterial disease and heart failure. These trials covered the spectrum of patients with heart failure.
The findings of this meta-analysis suggest…
View more
« First